Search results for "necrosis"

showing 10 items of 1354 documents

Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury.

2019

Abstract Background Nephrotoxic drug prescription may contribute to acute kidney injury (AKI) occurrence and worsening among critically ill patients and thus to associated morbidity and mortality. The objectives of this study were to describe nephrotoxic drug prescription in a large intensive-care unit cohort and, through a case–control study nested in the prospective cohort, to evaluate the link of nephrotoxic prescription burden with AKI. Results Six hundred and seventeen patients (62%) received at least one nephrotoxic drug, among which 303 (30%) received two or more. AKI was observed in 609 patients (61%). A total of 351 patients were considered as cases developing or worsening AKI a gi…

medicine.medical_specialtyIntensive-care units [MeSH]Critical Care and Intensive Care Medicine[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and NephrologyMESH: Vancomycin03 medical and health sciences0302 clinical medicineMESH: Kidney tubular necrosisRenal insufficiency [MeSH]Internal medicineAnesthesiologyMESH: Renal insufficiencymedicineMESH: Intensive-care unitsKidney tubular necrosisMESH: Diuretics030212 general & internal medicineMedical prescriptionSimplified Acute Physiology ScoreProspective cohort studyMESH: Acutebusiness.industryResearchAcute kidney injurylcsh:Medical emergencies. Critical care. Intensive care. First aidMESH: Aminoglycosides030208 emergency & critical care medicineOdds ratiolcsh:RC86-88.9[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesmedicine.diseaseVancomycin [MeSH][SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and NephrologyDiuretics [MeSH]3. Good health[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciencesContrast media [MeSH]CohortMESH: Contrast mediaAminoglycosides [MeSH]businessAcute [MeSH]Kidney diseaseAnnals of intensive care
researchProduct

Sequential release of TNFα and phospholipase A2 in a rat model of LPS-induced pleurisy

1997

The levels of extracellular phospholipase A2(sPLA2) and TNFα, and cell accumulation were measured in the pleural washings obtained at different times following the induction ofEscherichia colilipopolysaccharide (LPS, 100 μg/cavity) pleurisy in rats. TNFα peaked at 2 hours (3036 ± 160.3 units/ml) and decreased thereafter. Conversely, levels of sPLA2peaked at 48 hours (1.97 ± 0.64 ng/ml) and were increased further (14.02 ± 4.16 ng/ml) by pretreatment with anti-TNFα antibody. Cell accumulation was not affected by antibody pretreatment. These data indicate that the sPLA2enzyme is involved in LPS-induced pleurisy. The enzyme seems not to be stimulated by TNFα which may be involved in the downreg…

medicine.medical_specialtyLipopolysaccharideImmunologypleurisyInflammationchemistry.chemical_compoundPhospholipase A2Downregulation and upregulationInternal medicinemedicineExtracellularlcsh:Pathologyratchemistry.chemical_classificationbiologybusiness.industrylipopolysaccharideCell Biologymedicine.diseaseEndocrinologyEnzymechemistryPleurisyImmunologybiology.proteinTumor necrosis factor alphaphospholipase A2medicine.symptombusinessResearch Articlelcsh:RB1-214Mediators of Inflammation
researchProduct

Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and…

1997

We have tested whether tetracyclines (TETs) are able to protect mice from lipopolysaccharide (LPS)-induced shock, a cytokine-mediated inflammatory reaction. Mice, injected with a single dose of tetracycline base (TETb; 1.5, 10 and 20 mg/kg of body weight) or doxycycline (DOXY; 1.5 mg/kg), were significantly protected from a lethal intraperitoneal injection of LPS (500 micrograms per mouse). TETs acted in early events triggered in response to LSP; in fact, they were no longer significantly protective if injected more than 1 h after the injection of endotoxin. LPS-treated mice protected by TETs showed a significant inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin-1 alpha (IL…

medicine.medical_specialtyLipopolysaccharidemedicine.medical_treatmentIntraperitoneal injectionDown-RegulationAlpha (ethology)SpleenBiologyMicechemistry.chemical_compoundInternal medicinemedicineAnimalsPharmacology (medical)LungAntibacterial agentPharmacologyMice Inbred BALB CNitratesTumor Necrosis Factor-alphaTetracyclineShock SepticEndotoxemiaAnti-Bacterial AgentsNitric oxide synthaseInfectious DiseasesEndocrinologyCytokinemedicine.anatomical_structurechemistryDoxycyclineEnzyme InductionMacrophages Peritonealbiology.proteinCytokinesFemaleTumor necrosis factor alphaNitric Oxide SynthaseInjections IntraperitonealSpleenInterleukin-1Research ArticleAntimicrobial Agents and Chemotherapy
researchProduct

Spontaneous bisphosphonate-related osteonecrosis of the left hemi-mandible: Similarities with phossy jaw.

2013

Intravenous bisphosphonates (BP) play a key role in the treatment of bone metastases. As a long-term side effects BP, a form of avascular osteonecrosis of the jaw has been reported. Although, invasive oral local procedures are often present in clinical history of patients suffering from bisphosphonates-related osteonecrosis of the jaws (BRONJ), about up to 50% of BRONJ are spontaneous. We report a case of a 68-year-old female with a spontaneous wide bone sequestration of the left mandibular body onset after infusion of zoledronic acid for 18 cycles for osseous metastasis due to metastatic anaplastic thyroidal carcinoma. Surprisingly the clinical aspects of the patient initially reminded us …

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentBone NeoplasmsZoledronic AcidBone sequestrationstomatognathic systemMandibular bodySettore MED/28 - Malattie OdontostomatologichemedicineCarcinomaHumansMandibular DiseasesThyroid Neoplasmsthyroidal carcinomaGeneral DentistryAgedPhossy jawBone Density Conservation AgentsDiphosphonatesbusiness.industryCarcinomaMandibleImidazolesBisphosphonatesGeneral MedicineBisphosphonatemedicine.diseaseBisphosphonatesbisphosphonates‑related osteonecrosis of the jaws thyroidal carcinoma zoledronic acidbisphosphonates-related osteonecrosis of the jawsSurgerylcsh:RK1-715stomatognathic diseasesZoledronic acidlcsh:DentistryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugFollow-Up Studies
researchProduct

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents

2015

Background The clinical management of medication-related osteonecrosis of the jaw (MRONJ) in patients treated with bisphosphonates and other antiresorptive agents is subject to controversy. The American Association of Oral and Maxillofacial Surgeons (AAOMS) has developed guidelines for the correct management of the disorder which are revised and updated by a panel of experts. Material and Methods The present systematic review analyzes the different treatments currently used to treat this clinical condition, based on the PRISMA® (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement published in 2009. An electronic Medline search was made of the PubMed database, cover…

medicine.medical_specialtyMEDLINEAlternative medicineDentistryDiseaseReview03 medical and health sciences0302 clinical medicineAntiresorptive AgentsmedicineHumansStage (cooking)Intensive care medicineGeneral DentistryBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosis030206 dentistrymedicine.diseaseMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngology030220 oncology & carcinogenesisTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jaw
researchProduct

American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to ref…

2009

With reference to the 2009 update of the American Association of Oral and Maxillofacial Surgeons posi- tion paper, Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ), a relevant modification to the previous classification has been made and a new stage (0) added. The latter stage has been defined as “patients with no clinical evidence of necrotic bone, but who present with nonspecific symptoms or clinical and radiographic findings . . .” and the need for various clinical and radiologic aspects in defining this condi- tion was confirmed. .

medicine.medical_specialtyMaxillofacial surgeonsbusiness.industryGeneral surgerymedicine.medical_treatmentAssociation (object-oriented programming)MEDLINEBisphosphonateOtorhinolaryngologySettore MED/28 - Malattie OdontostomatologichePosition paperMedicineSurgeryOral SurgerybusinessBisphosphonates Osteonecrosis Jaws
researchProduct

Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)

2012

Dear Editor, It is the authors’ belief that the internationally accepted definition of bisphosphonate-related osteonecrosis of the jaws (BRONJ) (Ruggiero et al, 2009) has several limitations that prevent clinicians from being confident with the diagnosis of the disease. Following recognition of the non-exposed BRONJ clinical variant (Lazarovici et al, 2009), we all became aware that the presence of ‘exposed necrotic bone in the oral cavity’, as outlined in the American Association of Oral and Maxillofacial Surgery (AAOMS) case definition, is just one of the possible clinical manifestations of BRONJ and is not found in all BRONJ patients. As ‘bone exposure’ is certainly not the initial sign …

medicine.medical_specialtyMedullary cavityBone diseaseBiopsymedicine.medical_treatmentSettore MED/29 - Chirurgia MaxillofaccialeDiagnosis DifferentialSettore MED/28 - Malattie OdontostomatologicheTerminology as TopicOral and maxillofacial pathologymedicineHumansGeneral DentistryBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryDecision TreesBisphosphonatemedicine.diseaseSurgeryOtorhinolaryngologybisphosphonate-related osteonecrosis of the jawOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawDifferential diagnosisOsteonecrosis of the jawbusiness
researchProduct

Hepatocellular Hyperplasia, Plasmacytoma Formation, and Extramedullary Hematopoiesis in Interleukin (IL)-6/Soluble IL-6 Receptor Double-Transgenic Mi…

1998

Cytokines interact not only with membrane anchored receptors, but also with specific soluble receptors which circulate in the bloodstream. In general, soluble cytokine receptors such as soluble tumor necrosis factor receptor, soluble interleukin 1 receptor, and soluble interleukin 4 receptor compete with their membrane-bound counterparts for the ligands and therefore act as antagonists. In contrast, soluble receptors for cytokines of the interleukin-6 (IL-6) family complex with their ligands act agonistically. Interestingly, the complex of IL-6 and the soluble interleukin 6 receptor (sIL-6R) activates target cells that do not express the membrane-bound IL-6R and therefore cannot respond to …

medicine.medical_specialtyMice TransgenicInterleukin 1 receptor type IIInterleukin-1 receptorPathology and Forensic MedicineMiceNecrosisInterleukin-4 receptorInternal medicinemedicineAnimalsHumansReceptorInterleukin 6HyperplasiabiologyInterleukin-6Body WeightLiver NeoplasmsInterleukinAnimal ModelsOrgan SizeReceptors Interleukin-6EndocrinologyLiverHematopoiesis ExtramedullaryInterleukin-6 receptorCancer researchbiology.proteinInterleukin 1 receptor type ISpleenPlasmacytomaThe American Journal of Pathology
researchProduct

New approaches in the treatment of Adamantiades-Behçet's disease.

2005

Purpose of review To update clinicians on the recent advances in the treatment of Adamantiades-Behcet's disease. Recent findings Interferon-α-2a and infliximab have proved able to induce prompt remission in the vast majority of Adamantiades-Behcet's patients with DMARD-resistant uveoretinitis. Efficacy of interferon-α-2a has also been reported for mucocutaneous lesions, arthritis, and (more anecdotally) for neuro-Behcet, while results from small case series suggest that infliximab is beneficial for mucocutaneous lesions and (more anecdotally) for arthritis and gastro-intestinal manifestations. Two cases of neuro-Behcet treated with infliximab showed a complete resolution. Finally, in a rand…

medicine.medical_specialtyMucocutaneous zoneArthritisBehcet's diseaseDiseaseInterferon alpha-2Receptors Tumor Necrosis Factorlaw.inventionEtanerceptEtanerceptRheumatologyRandomized controlled triallawAntibodies Monoclonal; Behcet Syndrome; Chaperonin 60; Humans; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Receptors Tumor Necrosis Factor; Recombinant ProteinsmedicineHumansImmunologic FactorsIFN-α2abusiness.industryBehcet SyndromeAntibodies MonoclonalInterferon-alphaChaperonin 60medicine.diseaseDermatologyeye diseasesInfliximabAdamantiades-Behçet's diseaseInfliximabRecombinant Proteinsstomatognathic diseasesImmunoglobulin GImmunologyTumour necrosis factorbusinessTolerizationUveitismedicine.drugCurrent opinion in rheumatology
researchProduct

Mucormycosis of maxilla following tooth extraction in immunocompetent patients : reports and review

2018

Mucormycosis is a rare, fulminant, rapidly spreading fungal infection, which usually affects patient with underlying immune deficiency. If not managed promptly, the disease is characterized by progressive necrosis and is often fatal. A review of English literature shows that only fourteen cases of mucormycosis have been reported after tooth extraction. This paper highlights two cases of mucormycosis subsequent to tooth extraction in healthy adult patients. This first patient presented with an oroantral fistula and extensive maxillary necrosis. Whereas the second case was localized and presented as non-healing extraction socket with alveolar necrosis. This adds two more cases of this rare an…

medicine.medical_specialtyNecrosisAdult patientsbusiness.industryFulminantMucormycosisCase Report030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Surgery03 medical and health sciences0302 clinical medicineOroantral fistulaMaxillaUNESCO::CIENCIAS MÉDICASmedicineZygomycosismedicine.symptomOral SurgeryComplicationbusinessGeneral Dentistry030217 neurology & neurosurgery
researchProduct